New stroke drug aims to cut disability in first 3 hours
NCT ID NCT07520565
First seen Apr 21, 2026 · Last updated Jun 23, 2026 · Updated 8 times
Summary
This phase 3 trial tests whether a single injection of BXOS110, given within 3 hours of an acute ischemic stroke, can reduce overall disability compared to a placebo. About 1112 adults aged 18-85 with moderate to severe stroke are being enrolled. The main goal is to see if more people achieve functional independence (mRS score 0-2) at 90 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital , Capital Medical University
NOT_YET_RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Daqing Oilfield General Hospital
RECRUITINGDaqing, Heilongjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harrison International Peace Hospital
RECRUITINGHengshui, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linfen Central Hospital
NOT_YET_RECRUITINGLinfen, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linyi People's Hospital
RECRUITINGLinyi, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MeiHekou Central Hospital
RECRUITINGMeihekou, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Shenyang Medical College
RECRUITINGShenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Nanyang Medicinal College
RECRUITINGNanyang, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xianyang Hospital of Yan'an University
RECRUITINGXianyang, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BXOS110 injection
What this could lead to
If successful, this could provide a new treatment option to reduce long-term disability after a stroke.
What could go wrong
This is a single-dose study in a narrow 3-hour window, so many patients may not benefit. The trial is still recruiting, and results are not yet known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.